Literature DB >> 17957794

Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma.

Léon C L T van Kempen1, Jos Rijntjes, Ine Mamor-Cornelissen, Silvia Vincent-Naulleau, Marie-Jeanne P Gerritsen, Dirk J Ruiter, Marcory C R F van Dijk, Claudine Geffrotin, Goos N P van Muijen.   

Abstract

Tumors are complex tissues composed of neoplastic cells, soluble and insoluble matrix components and stromal cells. Here we report that in melanoma, turn-over of type I collagen (Col(I)), the predominant matrix protein in dermal stroma affects melanoma progression. Fibroblasts juxtaposed to melanoma cell nests within the papillary dermis display high levels of Col(I) mRNA expression. These nests are enveloped by collagen fibers. In contrast, melanoma-associated fibroblasts within the reticular dermis express Col(I) mRNA at a level that is comparable to its expression in uninvolved dermis and reduced amount of collagen protein can be observed. To determine the significance of Col(I) expression in melanoma, we pharmacologically inhibited its transcription in a porcine cutaneous melanoma model by oral administration of halofuginone. When administered before melanoma development, it reduced melanoma incidence and diminished the transition from microinvasive toward deeply invasive growth by limiting the development of a tumor vasculature. Whereas invasive melanoma growth has been correlated with increased blood vessel density previously, our data for the first time demonstrate that the proangiogenic effect of Col(I) expression by fibroblasts and vascular cells precedes the development of invasive melanomas in a de novo tumor model. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17957794     DOI: 10.1002/ijc.23147

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

1.  Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness.

Authors:  Njainday Pulo Jobe; Daniel Rösel; Barbora Dvořánková; Ondřej Kodet; Lukáš Lacina; Rosana Mateu; Karel Smetana; Jan Brábek
Journal:  Histochem Cell Biol       Date:  2016-04-21       Impact factor: 4.304

2.  What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?

Authors:  Constance E Brinckerhoff
Journal:  Melanoma Manag       Date:  2016-02-18

3.  A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma.

Authors:  Benjamin Mann; Milan Madera; Iveta Klouckova; Yehia Mechref; Lacey E Dobrolecki; Robert J Hickey; Zane T Hammoud; Milos V Novotny
Journal:  Electrophoresis       Date:  2010-06       Impact factor: 3.535

4.  Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.

Authors:  Iara F Kretzer; Durvanei A Maria; Raul C Maranhão
Journal:  Cell Oncol (Dordr)       Date:  2012-10-03       Impact factor: 6.730

Review 5.  Emerging Role of Syndecans in Extracellular Matrix Remodeling in Cancer.

Authors:  Bohee Jang; Ayoung Kim; Jisun Hwang; Hyun-Kuk Song; Yunjeon Kim; Eok-Soo Oh
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 6.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms.

Authors:  Faheem M Shaikh; Eric C Seales; William C Clem; Kristin M Hennessy; Ya Zhuo; Susan L Bellis
Journal:  Exp Cell Res       Date:  2008-07-30       Impact factor: 3.905

8.  Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.

Authors:  Diego L Viale; Eduardo G Cafferata; David Gould; Cecilia Rotondaro; Yuti Chernajovsky; David T Curiel; Osvaldo L Podhajcer; M Veronica Lopez
Journal:  J Invest Dermatol       Date:  2013-04-19       Impact factor: 8.551

Review 9.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

10.  Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.

Authors:  Léon C van Kempen; Karin van den Hurk; Vladimir Lazar; Stefan Michiels; Véronique Winnepenninckx; Marguerite Stas; Alan Spatz; Joost J van den Oord
Journal:  Virchows Arch       Date:  2012-09-06       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.